No effect of insulin treatment or glycemic improvement on plasma carnitine levels in type 2 diabetic patients.
Carnitine is an essential factor for the transport of long-chain fatty acids and is important for the heart muscle. A longitudinal study in type 2 diabetic patients was carried out. Carnitine levels were observed before and during metabolic intervention with dietary measures and either sulfonylurea or insulin treatment. In both treatment groups a significant glycemic improvement was observed after 3 months (insulin treatment group: hemoglobin A1c 11.3 +/- 2.8 versus 7.0 +/- 1.0; sulfonylurea treatment group; hemoglobin A1c 11.3 +/- 1.4 versus 7.3 +/- 0.9). Carnitine levels did not differ from a control group and did not change significantly during the observed period.
Pregant
P
P
I. Medizinische Abteilung der Krankenanstalt Rudolfstiftung.
Kaiser
E
E
Schernthaner
G
G
D000368:Aged; D001786:Blood Glucose / Q000378:metabolism*; D002331:Carnitine / Q000097:blood*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007328:Insulin / Q000627:therapeutic use*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged
D001786:Blood Glucose; D007328:Insulin; D002331:Carnitine